Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure
Status:
Terminated
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
This study is a multi-center, prospective, randomized, double blind, placebo-controlled
clinical trial. Subjects in the study will be adults with New York Heart Association (NYHA)
Class II-IV heart failure (HF) due to left ventricular systolic dysfunction (LVSD), left
ventricular ejection fraction (LVEF) <0.40, and secondary pulmonary hypertension (PH). The
purpose of the study is to evaluate the safety, effectiveness, and effects of tadalafil
compared to placebo on the subjects' functional capacity / quality of life.
Phase:
Phase 3
Details
Lead Sponsor:
HealthCore-NERI New England Research Institutes
Collaborators:
Massachusetts General Hospital National Heart, Lung, and Blood Institute (NHLBI)